Important safety benchmark: 14/101 deaths not related to disease progression (13.9%) I think we need to do better at preventing infections in this patient population. Much to be characterized re. immune reconstitution post CD19 CAR Joshua Hill, MD 2/2

The iciHHV-6 sense: sensing the source and relevance of human herpesvirus 6 (HHV-6) DNA in the transplant recipient with inherited chromosomally integrated HHV-6 ✅ Just Accepted 🔗 bit.ly/3V9KJiX

In other #pandemic news ... let's do better next time! "It is paramount to plan 4 future pandemics by investing in specific #clinicaltrial infrastructure 4 the #immunocompromised population to be prepared when the need arises." academic.oup.com/cid/article/do…

Herpes cure with gene editing makes progress in laboratory studies Virologists Fred Hutchinson Cancer Center UW Virology eliminated >90% of HSV-1 in preclinical models of oral and genital #herpes and reduced viral shedding #HSV #virology fredhutch.org/en/news/releas…

How Immunocompromised Hosts Were Left Behind in the Quest to Control the Covid-19 Pandemic ✅ Just Accepted 🔗 bit.ly/4aNsxQR

The impact of prior COVID-19 on non-infectious endothelial complications following allogeneic hematopoietic stem cell transplantation ✅ Just Accepted bit.ly/3RFoZcP

Reactivation of a Transplant Recipient's Inherited Human Herpesvirus 6 and Implications to the Graft ✅ Just Accepted 🔗 bit.ly/3Xakfzt

Great data from Danniel Zamora, MD establishing pre-HCT #CMV reactivation as an important risk factor for post-HCT CMV viremia and end-organ disease. Nice work, Danny!

#COVID19 can be a dangerous infection, particularly in people who recently got #BMT or #CAR-T therapy. Revaccination after BMT is important to boost immunity. Learn more about this BMT CTN study: cibmtr.org/Files/Patient-…

🚨 hot off the press 🚨 A (perhaps) underestimated aspect of CAR T-cell therapy: non-relapse mortality. Check out our new meta-analysis on this clinically relevant topic - out today in Nature Medicine ! nature.com/articles/s4159… Let’s take a deeper dive! Start 🧵

Just out Nature Medicine meta-analysis >7600 CAR T pts led by David Cordas dos Santos & Kai Rejeski - Non-relapse mortality post CAR-T = 6.8% - highest w ciltacel (15%) & brexucel (10.6%) - axicel (7%) > tisa-/lisocel (4%) for LBCL - 51% of NRM deaths from infection nature.com/articles/s4159…

Interesting how many of these infections were not specified in terms of diagnosis! We NEED improved diagnostics and infection reporting to better understand how to prevent and manage infections in this setting! Erika Kampouri Joshua Hill, MD Bilal Abid, MD, MS

Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia bit.ly/4fiT9wF

Hot off the press, great team effort for #ID guidance in #CART: Best Practice Considerations by The American Society of Transplant and... sciencedirect.com/science/articl… Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 Tania Jain M. Veronica Dioverti Nirali Shah genovefa papanicolaou Mehdi Hamadani, MD ASTCT

#CART ID practices effort — kudos to Zainab Shahid MD, FACP, FIDSA 🇺🇸🇵🇰 for leading this and rescuing this effort from ASTCT , and to all contributors for the critical contributions Martina Pennisi Joshua Hill, MD Swetha Kambhampati Lekha Mikkilineni and others

Bispecific antibody therapy is a novel immunotherapy 💊 for hematologic malignancies, but opportunistic infections 🦠remain a serious concern. Here we report the first case of disseminated MAC infection in a patient on BsAb tx Ben Teh Eddie Cliff academic.oup.com/ofid/advance-a…

JOB POSTING: CIBMTR is seeking a part time (0.1 FTE) Scientific Director to lead our Infection and Immune Reconstitution Working Committee. Learn more about this important position, here: cibmtr.org/Files/Careers1… NMDP

Hypogammaglobulinemia, infections/severe infections, and antimicrobial use were decreased in patients with CLL or NHL treated with IgRT. ow.ly/tCYK50T7N6E #lymphoidneoplasia #healthservicesandoutcomes